Date: Tuesday, October 24, 2023
Time: 2:00pm – 3:00pm ET

TITLE:
A Clinical Overview and Update from Sanofi for Efanesoctocog Alfa, A High Sustained Factor VIII Therapy

OBJECTIVES:

1. Highlighting both Efanesoctocog Alfa’s pediatric study, the XTEND-Kids data that were presented at ISTH 2023, as well as an observational study of patients who switched from current therapy to Efanesoctocog Alfa prophylaxis.
2. Highlighting available lab monitoring program available to your centers.

TARGET AUDIENCE:
All HTC Staff

SPEAKER:

Nancy Epp, PharmD, BCACP

Nancy Epp is a Senior Medical Science Liaison with Sanofi. She supports the Sanofi hemophilia A and B portfolio to provide up-to-date scientific data to healthcare providers. Nancy is based in Houston, Texas, and can be reached by email at Nancy.Epp@sanofi.com.